证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2023-007 | --- | --- | --- | |----------------------------|----------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | □特定对象调研 □ | 分析师会议 | | 投资者关系活动类别 | □媒体采访 □□新闻发布会 □□现场参观 | 业绩 ...

证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2023-006 | --- | --- | --- | |----------------------------|----------------------------------------------------------|--------------------------------------------------------------------------------------------| | | □特定对象调研 □ | 分析师会议 | | 投资者关系活动类别 | □媒体采访 □□新闻发布会 □□√现场参观 | 业绩说明会路演活动 | | | □其他 | | | | | 建投投资余蔡一；天安人寿李勇钢；太平资产李涛；国泰租赁郭 | | | | 梦颖、宁雪帆；兴银资本张黎明；瑞华控股陶光绪；东方嘉富周 | | | | 辉；永安期货姚沁源；锦绣中和冯奕健；睿郡资产苏华立；涌津 | | 参与单位名称 | | 投资傅逞强；北京泰德圣基金李妮 ...

证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2023-005 | --- | --- | --- | |----------------------------|----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | □特定对象调研 □ | 分析师会议 | | 投资者关系活动类别 | □媒体采访 □□新闻发布会 □□√现场参观 | 业绩说明会√路演活动 | | | □其他 | | | | ...

证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2023-004 | --- | --- | |--------------------|------------------------------------------------------------| | | □分析师会议 | | 投资者关系活动类别 | □业绩说明会 □路演活动 | | | | | 参与单位名称 | 上海证券周海涛；善思投资张伟、李莹；正享投资袁婷婷；博时 | | 及人员姓名 | | | 时间 | 月 19 日 14:00-16:00 | | 地点 | 深圳市坪山区雷柏·中城生命科学园第三分园 A 栋 1 楼会议室 | | 上市公司接待 | 公司投资者关系管理总监：许益群 | | 人员姓名 | 公司证券事务代表：程筱玥 | | | 一、介绍公司基本情况 | | | 公司致力于为客户提供从产品设计、模具制造、产品生产到组装 | | | 的一站式服务，主要为医疗器械高分子塑料耗材领域、半导体晶 | | | 圆载具及办公自动化（OA）设备 ...

证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |------------------------|------------------------------------------|---------------------|----------| | | | | 2023-003 | | | □特定对象调研 □分析师会议 | | | | 投资者关系活动类别 | □媒体采访 □新闻发布会 □路演活动□现场参观 | □√ 业绩说明会 | | | | □其他 | | | | 参与单位名称及人员姓名 | 市场投资者 | | | | 时间 2023 | 年 5 月 8 日 | 15:00-17:00 | | | | 地点 全景网投资者关系互动平台（ | https://ir.p5w.net/ | ） | | --- | --- | |----------------|--------------------------------------------------- ...

Financial Performance - The company's revenue for Q1 2023 was ¥285,048,546.38, a decrease of 2.87% compared to ¥293,485,351.69 in the same period last year[6] - Net profit attributable to shareholders was ¥31,597,187.56, down 29.77% from ¥44,989,213.39 year-on-year[6] - Basic earnings per share decreased by 40.00% to ¥0.06 from ¥0.1 in the same period last year[6] - Net profit for the current period is CNY 29,234,957.77, down 38.3% from CNY 47,423,639.84 in the previous period[31] - The net profit attributable to the parent company is CNY 31,597,187.56, compared to CNY 44,989,213.39 in the previous period, reflecting a decline of 29.6%[31] - The total comprehensive income attributable to the parent company is CNY 29,512,437.03, down from CNY 41,241,495.07 in the previous period[31] Cash Flow - The net cash flow from operating activities was ¥14,255,531.63, representing a significant decline of 68.98% compared to ¥45,957,387.87 in the previous year[6] - Cash flow from operating activities is CNY 297,066,728.53, an increase from CNY 291,360,984.59 in the previous period, indicating improved cash generation[31] - Cash received from other operating activities was $9,202,130.49, compared to $32,352,261.44 in the previous period, indicating a decline of 71.5%[34] - Cash inflow from financing activities amounted to $21,100,000.00, while cash outflow was $14,005,803.07, leading to a net cash flow of $7,094,196.93, a decrease of 81.7% from $38,794,399.74[34] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,225,236,704.80, a slight decrease of 0.42% from ¥2,234,719,706.75 at the end of the previous year[6] - Total current assets decreased to RMB 1,075,925,832.54 from RMB 1,159,884,881.57, reflecting a reduction in cash and inventory levels[21] - Total liabilities decreased to RMB 846,020,744.76 from RMB 885,979,509.01, showing a reduction in financial obligations[24] - The total equity attributable to shareholders of the parent company increased to CNY 1,330,781,445.08 from CNY 1,295,002,591.59[27] Expenses - R&D expenses increased by 47.02% to RMB 14,691,600 from RMB 9,992,800 mainly due to increased stock incentive expenses for R&D staff compared to the same period last year[15] - Sales expenses decreased by 50.53% to RMB 5,456,900 from RMB 11,029,800 primarily due to reduced advertising and exhibition costs from subsidiaries[15] - Tax and additional fees decreased by 56.46% to RMB 739,500 from RMB 1,698,600 due to reduced local tax payments compared to the same period last year[15] Investment Activities - The company reported a non-recurring profit of ¥5,243,540.01 for the period, primarily from government subsidies and investment management gains[7] - Investment income surged by 353.85% to RMB 919,500 from RMB 202,600, driven by increased equity method gains from affiliated companies and bank wealth management income[15] - Cash received from investment activities totaled $191,833,281.44, significantly higher than $72,628,030.60 in the previous period[34] - Cash received from other investment activities was $190,400,000.00, a substantial increase from $65,833,123.29 in the previous period[34] Joint Ventures and Development - The company is involved in a joint venture with Hubei Dinglong Holdings Co., Ltd. to establish Zhejiang Dinglong Weibo Precision Technology Co., Ltd., focusing on semiconductor wafer carrier manufacturing[14] - The company is actively advancing the development and production of semiconductor-related products, with initial samples of wafer carriers already sent for testing[20]

Investment and Financial Performance - The total committed investment amount for the high-end medical equipment and consumables production line expansion project is CNY 32,500 million, with an actual investment of CNY 18,000.15 million during the reporting period[1]. - As of the end of the reporting period, the cumulative investment amount reached CNY 24,336.01 million, representing an investment progress of 74.88%[1]. - The realized benefits for the reporting period amount to CNY 1,682.49 million, with cumulative realized benefits of CNY 2,346.7 million[1]. - The total amount of raised funds for the committed investment projects is CNY 44,773.77 million, with a cumulative investment of CNY 36,609.78 million[1]. - The company reported a net profit of 5,270.41 million CNY from its subsidiary Shenzhen Baoming Sheng Medical Devices Co., Ltd., contributing over 10% to the overall net profit[9]. - The company reported total assets of 36,757.08 million CNY for Shenzhen Baoming Sheng Medical Devices Co., Ltd.[9]. - The company reported a total revenue of RMB 1.2 billion for the year 2022, representing a year-on-year increase of 15% compared to RMB 1.04 billion in 2021[54]. - The net profit for 2022 was reported at RMB 300 million, a 10% increase from RMB 272 million in 2021, demonstrating strong financial performance[54]. - The company's operating revenue for 2022 was ¥1,228,311,379.34, representing an increase of 8.95% compared to ¥1,127,382,018.70 in 2021[64]. - The net profit attributable to shareholders for 2022 was ¥127,876,738.63, up 14.34% from ¥111,841,084.78 in 2021[64]. - The net cash flow from operating activities for 2022 was ¥218,279,077.59, a remarkable increase of 124.78% compared to ¥97,106,056.55 in 2021[64]. - The company has set a performance guidance for 2023, projecting a revenue target of RMB 1.5 billion, which would represent a growth of 25% year-on-year[54]. Project Development and Future Plans - The project is expected to reach its predetermined usable status by March 31, 2024[1]. - The company plans to enhance its core competitiveness in the medical device and consumables sector through continuous R&D investment and engineering innovation[13]. - The company plans to strategically expand its international business to enhance economic growth channels and improve overall profitability[16]. - The company aims to explore multiple fields through technological innovation and key project breakthroughs, focusing on the medical device and semiconductor industries[30]. - The company aims to launch three new medical device products in 2023, which are expected to contribute an additional RMB 200 million in revenue[54]. - The company is exploring potential acquisition opportunities in the medical technology sector to further enhance its product offerings and market share[54]. - The company is constructing a proprietary medical consumables production base to enhance production capacity and core competitiveness[118]. Research and Development - The company plans to strengthen its talent pool by enhancing internal training and external recruitment, implementing a comprehensive incentive mechanism[31]. - Research and development expenses increased by 25% to RMB 150 million in 2022, reflecting the company's commitment to innovation and new product development[54]. - The company has established a comprehensive innovation R&D platform, with 163 authorized patents as of December 31, 2022, including 43 patents granted in 2022[113]. - The company has a strong focus on R&D in advanced diagnostic technologies, including molecular diagnostics and immunodiagnostics, to enhance disease prevention capabilities[78]. - The company is developing multi-channel pipette injection molds to meet the high demand for pipettes in medical research, with the project currently in the mass production and process optimization stage[157]. - The core component injection molds for external injectors are under development, focusing on solving complex structural challenges, which will enhance the company's competitive edge in high-end medical injection molds[157]. Market Strategy and Customer Engagement - The company emphasizes a customer-centric approach and aims to become a one-stop service provider in the medical device and consumables market[14]. - The company has initiated a strategic partnership with a leading healthcare provider to enhance distribution channels and improve market penetration[54]. - The company aims to continue deepening its market presence in the medical device sector while consolidating its market share in precision molds and OA products[110]. - The company is focused on expanding its market influence both domestically and internationally through product innovation and technology advancement[153]. Operational Efficiency and Management - The company will focus on optimizing production and enhancing management efficiency to strengthen its competitive advantage in high-end manufacturing[15]. - The company has established a strict quality management system for raw material procurement, ensuring high-quality inputs for its products[102]. - The company has a strong operational management system that ensures effective quality and production efficiency, contributing to its market competitiveness[117]. - The company has introduced several information management systems, enhancing precision management and laying a solid foundation for performance management[134]. Financial Management and Fund Utilization - The company has established a dedicated account for the management of raised funds, ensuring strict approval processes for their use, in compliance with the tripartite supervision agreement[25]. - There are no issues or other situations regarding the use and disclosure of raised funds[3]. - The company plans to use the raised funds to replace pre-invested self-raised funds and issuance expenses totaling CNY 61,186,323.06[3]. - The company has not engaged in any securities or derivative investments during the reporting period[22][23]. - The company has not made any changes to the investment projects or their implementation locations[1]. Industry Trends and Regulatory Environment - The medical device industry in China is projected to reach ¥1.3 trillion in revenue for 2022, making it the second-largest medical device market globally[77]. - The domestic medical device market is characterized by a large number of small and scattered local enterprises, with multinational companies holding a significant market share in high-value consumables and medical equipment[79]. - The "14th Five-Year Plan" emphasizes the importance of developing core technologies in pharmaceuticals and medical devices, aiming to enhance disease diagnosis capabilities and promote early screening for major diseases[78]. - The government is encouraging the localization and innovation of medical devices through policies that support domestic enterprises and promote high-quality development in the industry[81]. - The medical device industry is experiencing rapid growth driven by healthcare system reforms and the demand for domestic alternatives[81].

本次年度业绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投 资者关系互动平台"（http://ir.p5w.net）参与本次年度业绩说明会。 | 证券代码: 300151 | 证券简称：昌红科技 | 公告编号：2023-022 | | --- | --- | --- | | 债券代码: 123109 | 债券简称: 昌红转债 | | 深圳市昌红科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 深圳市昌红科技股份有限公司（以下简称"公司"）于 2023 年 4 月 25 日在 创业板指定信息披露网站巨潮资讯网上披露了《2022 年年度报告》及《2022 年 年度报告摘要》。为便于广大投资者更深入全面地了解公司 2022 年度经营情况， 公司定于 2023 年 5 月 8 日（星期一）下午 15:00-17:00 在全景网举办 2022 年度 业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长兼总经理李焕昌先生、独立 董事张锦慧女士、财务总监周国铨先生、副总经理兼董事会秘书刘力先生。 为充 ...

Business Overview - Changhong Technology has been operating for 22 years, focusing on "one-stop" solutions in the medical device and consumables sector, as well as mold and OA equipment [2] - The company has successfully entered the supply chains of international and domestic industry giants, including Roche, with whom it signed a strategic cooperation agreement in 2021 [3] - Changhong Technology's vision is to become a global leader, providing world-class products to domestic clients and contributing to the improvement of Chinese manufacturing standards [3] Zhejiang Boming Sheng Industrial Park - The company established Zhejiang Boming Sheng in January 2021 to develop its medical device and consumables business, with an investment in a high-molecular medical consumables industrial park [2] - The park covers an area of 106,500 square meters, with a planned construction area of 158,000 square meters, including 7 factory buildings, 1 dormitory, and 1 R&D building [2] - Construction began in March 2021, with external infrastructure completed and internal factory decoration and supporting projects underway [2] Dinglong Weibai Business - Dinglong Weibai focuses on wafer carriers, which are used for storage, transfer, transportation, and protection of wafers during processing [3] - The wafer carrier industry has high technical, financial, and R&D barriers, with a concentrated global market dominated by a few US and Japanese companies [3] - Dinglong Weibai aims to establish a modern factory and automated intelligent production line, leveraging the strengths of both Dinglong and Changhong Technology [3] Financial and Operational Data - As of Q3 2022, Changhong Technology's R&D team consists of 263 people, accounting for 10.29% of the total workforce [3] - Mold business revenue accounts for approximately 10% of total revenue, with 52.34 million yuan in H1 2022, representing 9.21% of total revenue [3] - Traditional OA business revenue grew by 14.58% year-on-year to 316.26 million yuan, with stable domestic and overseas production [4] Future Plans - The company plans to prioritize new capacity in the Shangyu plant over the next three years, as the Shenzhen plant is currently at full capacity [4] - Changhong Technology aims to enhance its internationalization level and contribute to the "independent and controllable" strategy of the national semiconductor industry chain [3]